# Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

> **NCT04954859** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 450 (estimated)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Bepirovirsen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04954859
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-14
- **Primary completion:** 2029-02-08
- **Final completion:** 2029-02-08
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04954859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04954859, "Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04954859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*